跳轉至內容
Merck
  • Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.

Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.

BMC cancer (2015-04-18)
Stine L Figenschau, Silje Fismen, Kristin A Fenton, Christopher Fenton, Elin S Mortensen
摘要

Tertiary lymphoid structures (TLS) are highly organized immune cell aggregates that develop at sites of inflammation or infection in non-lymphoid organs. Despite the described role of inflammation in tumor progression, it is still unclear whether the process of lymphoid neogenesis and biological function of ectopic lymphoid tissue in tumors are beneficial or detrimental to tumor growth. In this study we analysed if TLS are found in human breast carcinomas and its association with clinicopathological parameters. In a patient group (n = 290) who underwent primary surgery between 2011 and 2012 we assessed the interrelationship between the presence of TLS in breast tumors and clinicopathological factors. Prognostic factors were entered into a binary logistic regression model for identifying independent predictors for intratumoral TLS formation. There was a positive association between the grade of immune cell infiltration within the tumor and important prognostic parameters such as hormone receptor status, tumor grade and lymph node involvement. The majority of patients with high grade infiltration of immune cells had TLS positive tumors. In addition to the degree of immune cell infiltration, the presence of TLS was associated with organized immune cell aggregates, hormone receptor status and tumor grade. Tumors with histological grade 3 were the strongest predictor for the presence of TLS in a multivariate regression model. The model also predicted that the odds for having intratumoral TLS formation were ten times higher for patients with high grade of inflammation than low grade. Human breast carcinomas frequently contain TLS and the presence of these structures is associated with aggressive forms of tumors. Locally generated immune response with potentially antitumor immunity may control tumorigenesis and metastasis. Thus, defining the role of TLS formation in breast carcinomas may lead to alternative therapeutic approaches targeting the immune system.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
过氧化氢 溶液, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
过氧化氢 溶液, 50 wt. % in H2O, stabilized
Sigma-Aldrich
过氧化氢溶液, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Millipore
过氧化氢 溶液, 3%, suitable for microbiology
Supelco
过氧化氢 溶液, ≥30%, for trace analysis
Sigma-Aldrich
过氧化氢 溶液, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
过氧化氢 溶液, purum p.a., ≥35% (RT)
Sigma-Aldrich
过氧化氢 溶液, 34.5-36.5%
Supelco
过氧化氢 溶液, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
过氧化氢 溶液, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
过氧化氢 溶液, tested according to Ph. Eur.
Sigma-Aldrich
过氧化氢 溶液, contains potassium stannate as inhibitor, 30-32 wt. % in water, semiconductor grade, 99.999% trace metals basis
Sigma-Aldrich
Goat Anti-Rat light chain Antibody, HRP conjugate, Chemicon®, from goat